Skip to content
Screener

Axsome Therapeutics AXSM Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$201.06B+4.0%
Alkermes logo
AlkermesALKS
$4.39B+95.0%
AbbVie logo
AbbVieABBV
$136.46B+0.2%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.3B+92.2%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$1.27B+20.5%

Other financials

Income statement

See full
Revenue$191.2M+57.4%
Gross profit$176.5M+58.0%
Operating income-$63.4M-11.2%
Net income-$64.5M-8.6%
EPS (diluted)-$1.26-3.3%

Balance sheet

See full
Cash & equivalents$305.1M+1.4%
Total debt$219.9M+4.1%
Total equity$54.6M+2.6%
Total assets$713.6M+19.6%

Cash flow

See full
Operating cash flow-$20.7M+52.3%
CapEx$121.0K-64.2%
Free cash flow-$20.8M+52.4%

Valuation

See full
Market cap$10.95B+113%
Enterprise value$10.87B+114%
P/S15.5×+5.1×

Profitability

See full
Gross margin92.6%+1.1pp
Operating margin-24.4%-9.3pp
Net margin-26.6%-9.8pp
FCF margin-10.2%-3.9pp

Returns & leverage

See full
Return on equity-349.4%+109pp
Debt / equity+0.1×
Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 5:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204274
Line itemMarch 31,2026December 31,2025
Total liabilities659,020601,510
Stockholders’ equity:
Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding)
Common stock, $0.0001 par value per share (150,000,000 shares authorized, 51,420,445 and 50,882,766 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively)55
Additional paid-in capital1,425,0851,394,251
Accumulated deficit(1,370,503)(1,305,961)
Total stockholders’ equity54,58788,295
Total liabilities and stockholders’ equity$713,607$689,805

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Axsome Therapeutics's total liabilities & equity?
Axsome Therapeutics (AXSM) reported total liabilities & equity of $713.61M in Q1 2026.
How has Axsome Therapeutics's total liabilities & equity changed year-over-year?
Axsome Therapeutics's total liabilities & equity increased by 19.6% year-over-year, from $596.67M to $713.61M.
What is the long-term trend for Axsome Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), Axsome Therapeutics's total liabilities & equity has grown at a 30.0% compound annual growth rate (CAGR), from $186.13M to $689.81M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Axsome Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude